All Posts

Assessing patient-centered outcomes in rare diseases is essential for understanding treatment benefit. However, patient heterogeneity introduces an extra layer of complexity in assessing outcomes. We have expertise in identifying concepts and developing endpoint strategies for rare heterogenous diseases, leveraging expertise from COA consulting, clinical development, and health economics and outcomes research.

In healthcare, improving patient outcomes is a primary goal that drives innovation. Clinical Outcome Assessments (COA) and Digital Health...

Our expertise in consulting and the pharmaceutical industry, encompassing clinical development, regulatory, and commercial functions,...

Clinical outcome assessment (COA), and broadly PED strategy, have become critical components in the development of patient-centric...